Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2022 08:00 ET | Source: Pharmazz, Inc.

Pharmazz Inc. announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to conduct a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates

Sovateltide is an endothelin-B receptor agonist that is neuroprotective, neurorestorative, and produces neurovascular remodeling Sovateltide marketing authorization for the treatment of acute...
May 25, 2022 08:00 ET | Source: Pharmazz, Inc.

Pharmazz Inc. Announces Positive Results of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke

Sovateltide produced a statistically significant and clinically meaningful improvement in neurological outcomes in acute cerebral ischemic stroke patients 90 days post-treatment Sovateltide...
March 10, 2022 08:00 ET | Source: Pharmazz, Inc.

Pharmazz Inc. announces FDA clearance of an IND application for a Phase II clinical trial of centhaquine (PMZ-2010) in COVID-19 patients with ARDS

WILLOWBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Pharmazz (“Pharmazz”), Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in...
February 17, 2022 08:00 ET | Source: Pharmazz, Inc.

Pharmazz Inc. Announces Completion of Enrollment of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke

WILLOWBROOK, Ill., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in...
February 03, 2022 08:00 ET | Source: Pharmazz, Inc.

Pharmazz Inc. submits Investigational New Drug Application to India Central Drugs Standard Control Organization for a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates

Sovateltide is an endothelin-B receptor agonist that has been shown to increase blood flow, show anti-apoptotic activity, and produce neurovascular remodeling Sovateltide is also in Phase III...

keyboard_arrow_left Previous Page